RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q2 2021
Top Holdings92 positions
ASCENDIS PHARMA A/S | 6.8M | $895.4M | 14.4% | $89.68 | +49.73% | 11 qtrssince 2018-Q4 | Increased 66 |
Novavax Inc | 2.6M | $543.5M | 8.7% | $107.78 | +93.86% | 5 qtrssince 2020-Q2 | Decreased 0 |
FORMA THERAPEUTICS HLDGS INC | 9M | $224.3M | 3.6% | — | — | 5 qtrssince 2020-Q2 | Unchanged 0 |
JANUX THERAPEUTICS INC | 8.7M | $216.3M | 3.5% | $25.37 | 0.00% | 1 qtr | New 85 |
VOR BIOPHARMA INC | 11.1M | $207.4M | 3.3% | $781.20 | -50.00% | 2 qtrssince 2021-Q1 | Unchanged 0 |
| 8.3M | $188.7M | 3.0% | — | — | 1 qtr | New 84 | |
Nkarta Inc | 5.6M | $177.6M | 2.9% | $30.36 | -2.24% | 4 qtrssince 2020-Q3 | Unchanged 0 |
MACROGENICS INC | 5.9M | $159.6M | 2.6% | $28.28 | -5.58% | 5 qtrssince 2020-Q2 | Increased 62 |
| 7M | $136.5M | 2.2% | $18.13 | +7.46% | 2 qtrssince 2021-Q1 | Increased 84 | |
TG Therapeutics Inc | 3.3M | $129.7M | 2.1% | $8.58 | +338.13% | 11 qtrssince 2018-Q4 | Decreased 0 |
ImmunoGen Inc | 18.4M | $121.4M | 1.9% | — | — | 4 qtrssince 2020-Q3 | Unchanged 0 |
ATEA PHARMACEUTICALS INC | 5.4M | $115.3M | 1.9% | $41.71 | -41.48% | 3 qtrssince 2020-Q4 | Unchanged 0 |
ITEOS THERAPEUTICS INC | 4.4M | $113.3M | 1.8% | — | — | 4 qtrssince 2020-Q3 | Increased 47 |
DAY ONE BIOPHARMACEUTICALS I | 5M | $113.1M | 1.8% | $22.21 | 0.00% | 1 qtr | New 69 |
AXSOME THERAPEUTICS INC | 1.7M | $111.7M | 1.8% | $50.95 | +36.71% | 10 qtrssince 2019-Q1 | Unchanged 0 |
PHATHOM PHARMACEUTICALS INC | 3.1M | $105.4M | 1.7% | $32.43 | +4.84% | 7 qtrssince 2019-Q4 | Unchanged 0 |
INSTIL BIO INC | 4.9M | $94.1M | 1.5% | $484.80 | -24.30% | 2 qtrssince 2021-Q1 | Unchanged 0 |
Rocket Pharmaceuticals Inc | 2.1M | $93.3M | 1.5% | $56.05 | -22.69% | 3 qtrssince 2020-Q4 | Unchanged 0 |
89bio Inc | 5M | $92.9M | 1.5% | — | — | 7 qtrssince 2019-Q4 | Increased 49 |
Zogenix Inc | 5.3M | $91.3M | 1.5% | — | — | 11 qtrssince 2018-Q4 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $6.2B across 92 positions as of Q2 2021. Top holdings: ASND (14.4%), NVAX (8.7%), FMTX (3.6%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
Active quarter - 20 new positions, 10 exits, 8 increased. Top move: JANX (NEW, conviction 85). Portfolio: $6.2B across 92 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR